Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: A pharmacoepidemiological programme comparing rosuvastatin with other marketed statins

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 12, 2010, Pages 1218-1224

  García Rodríguez, Luis A ^a   Herings, Ron ^b,c   Johansson, Saga ^d,e  

^a Department of Pharmacoepidemiology   (Spain)

^b PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d ASTRAZENECA R AND D   (Sweden)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

International; Multidatabase; Pharmacoepidemiology; Safety; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

ACUTE KIDNEY FAILURE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DATA BASE; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; HEALTH PROGRAM; HUMAN; KIDNEY INJURY; LIVER INJURY; MANTEL HAENSZEL TEST; MEDICAL INFORMATION SYSTEM; MEDICAL RECORD; META ANALYSIS; MORBIDITY; MYOPATHY; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; QUESTIONNAIRE; RHABDOMYOLYSIS; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VALIDATION PROCESS;

ACUTE KIDNEY INJURY; DATABASES, FACTUAL; DRUG-INDUCED LIVER INJURY; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; MUSCULAR DISEASES; PHARMACOEPIDEMIOLOGY; PYRIMIDINES; SULFONAMIDES;

EID: 78649496858     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2032     Document Type: Article

References (26)

1. Grundy SM. The issue of statin safety: where do we stand? Circulation 2005; 111(23): 3016-3019.
2. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292(21): 2585-2590.
3. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109(23 Suppl 1): III50-III57.
4. Evans M, Rees A. The myotoxicity of statins. Curr Opin Lipidol 2002; 13(4): 415-420.
5. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005; 41(4): 690-695.
6. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346(7): 539-540.
7. Davidson MH. Controversy surrounding the safety of cerivastatin. Expert Opin Drug Saf 2002; 1(3): 207-212.
8. Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J. Safety of rosuvastatin: update on 16, 876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007; 107(4): 433-443.
9. Johansson S, Ming EE, Wallander MA, et al. Rosuvastatin safety: a comprehensive, international pharmacoepidemiology programme. Pharmacoepidemiol Drug Saf 2006; 15(7): 454-461.
10. García-Rodríguez LA, Gonzalez EM, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 100 000 statin users in UK primary care. Pharmacoepidemiol Drug Saf 2008; 17(10): 943-952.
11. García-Rodríguez LA, Gonzalez-Perez A, Stang MR, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 25 000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiol Drug Saf 2008; 17(10): 953-961.
12. Goettsch WG, Heintjes EM, Kastelein JJ, Rabelink TJ, Johansson S, Herings RM. Results from a rosuvastatin historical cohort study in more than 45, 000 Dutch statin users, a PHARMO study. Pharmacoepidemiol Drug Saf 2006; 15(7): 435-443.
13. McAfee AT, Ming EE, Seeger JD, et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48, 000 initiators of statin therapy. Pharmacoepidemiol Drug Saf 2006; 15(7): 444-453.
14. Downey W, Stang M, Beck P, Osei W, Nichol J. Health services databases in Saskatchewan. In Pharmacoepidemiology, (4th edn) Strom BL (ed). John Wiley & Sons Ltd.: Chichester, UK, 2005; 295-310.
15. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23(5): 686-689.
16. Lanza LL, Dreyer NA, Shultz NJ. Use of insurance claims in epidemiological research: identification of peptic ulcer, GI bleeding, pancreatitis, hepatitis, and renal disease. Pharmacoepidemiol Drug Saf 1995; 4: 239-248.
17. Quam L, Ellis LB, Venus P, Clouse J, Taylor CG, Leatherman S. Using claims data for epidemiologic research. The concordance of claims-based criteria with the medical record and patient survey for identifying a hypertensive population. Med Care 1993; 31(6): 498-507.
18. ten Berg MJ, Huisman A, Souverein PC, et al. Drug-induced thrombocytopenia: a population study. Drug Saf 2006; 29(8): 713-721.
19. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA 1983; 249(13): 1743-1745.
20. Rothman K, Greenland S. Modern Epidemiology (3rd edn). Lippincott, Williams and Wilkins: Philadelphia, 2008.
21. Brewer HB, Jr Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003; 92(4B): 23K-29K.
22. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006; 97(8A): 61C-68C.
23. Institute of Medicine of the National Academies. The Future of Drug Safety, Promoting and Protecting the Health of the Public. The National Academies Press: Washington, DC, 2007.
24. European Commission: Enterprise and Industry. Rules Governing Medicinal Products in the European Union. Guidelines on Pharmacovigilance for Medicinal Products for Human Use. 2007. [accessed February 2010].
25. European Commission: Innovative Medicines Initiative. The Innovative Medicines Initiative (IMI) Strategic Research Agenda. Creating Biomedical R&D Leadership for Europe to Benefit Patients and Society. [accessed February 2010].
26. Johansson S, Wallander MA, de Abajo FJ, García-Rodríguez LA. Prospective drug safety monitoring using the UK primary-care General Practice Research Database: theoretical framework, feasibility analysis and extrapolation to future scenarios. Drug Saf 2010; 33: 223-232.